Changing paradigms in dermatology: Antivirals in dermatology

Clinics in Dermatology

Volumn 21, Issue 5, 2003, Pages 426-446

  Lin, Peggy ^b   Torres, Gisela ^b   Tyring, Stephen K ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; CHICKENPOX VACCINE; CIDOFOVIR; FAMCICLOVIR; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; HEPATITIS B VACCINE; IDOXURIDINE; IMIQUIMOD; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; PENCICLOVIR; PENTAMIDINE; PLACEBO; PROBENECID; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIFLURIDINE; UNINDEXED DRUG; VALACICLOVIR; VIDARABINE; VIRUS VACCINE; ZIDOVUDINE;

ABDOMINAL PAIN; ANEMIA; BEHAVIOR DISORDER; BONE MARROW SUPPRESSION; COMA; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; COUGHING; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DERMATOLOGY; DIABETES MELLITUS; DIARRHEA; DRUG BIOAVAILABILITY; EPSTEIN BARR VIRUS; ERYTHEMA; FATIGUE; GENITAL HERPES; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES LABIALIS; HERPES SIMPLEX; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOCALCEMIA; INFECTIOUS MONONUCLEOSIS; INFLUENZA; INFLUENZA VIRUS; INJECTION PAIN; INSOMNIA; KAPOSI SARCOMA; KIDNEY DISEASE; LETHARGY; LEUKOPENIA; LYMPHADENOPATHY; MOLLUSCUM CONTAGIOSUM; NAUSEA; NEPHROTOXICITY; NONHUMAN; PAPILLOMA VIRUS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURITUS; RASH; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SEIZURE; SIDE EFFECT; SKIN ULCER; SOMNOLENCE; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; VIRUS INFECTION; VIRUS TRANSMISSION; VOMITING; WHEEZING;

EID: 0347627151     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2003.08.012     Document Type: Article

References (104)

1. Meyer T., Arndt R., Christophers E., et al. Association of rare human papillomavirus types with genital premalignant and malignant lesions. J Infect Dis. 178:1998;252-255.
2. von Krogh G., Gross G. Anogenital warts. Clin Dermatol. 15:1997;355-368.
3. Brown T.J., Yen-Moore A., Tyring S.K. An overview of sexually transmitted diseases. Part I. J Am Acad Dermatol. 41:1999;511-529.
4. Vander Straten M, Carrasco D, Lee P, Tyring SK. A review of antiviral therapy for herpes labialis. Arch Dermatol 2001 Sep;137:1232-5.
5. Hill T.J. Herpes simplex virus latency. Roizman B. The herpesviruses. 1985;175-240 Plenum Publishing, New York, NY.
6. Glezen W.O., Fernald G.W., Lohr J.A. Acute respiratory disease of university students with special references to the etiologic role of herpesvirus hominis. Am J Epidemiol. 101:1975;111-121.
7. nd edition :1993;WB Saunders, Philadelphia, PA.
8. McCrary M.L., Severson J., Tyring S.K. Varicella zoster virus. J Am Acad Dermatol. 41:1999;1-14.
9. Brown T.J., Vander Straten M., Tyring S.K. Antiviral agents. Dermatol Clin. 19:2001;23-34.
10. Trizna Z., Tyring S.K. Antiviral treatment of diseases in pediatric dermatology. Dermatol Clin. 16:1998;539-552.
11. Epstein M.A., Morgan J.A. Clinical consequences of Epstein-Barr virus infection and possible control by an anti-viral vaccine. Clin Exp Immunol. 53:1983;257-271.
12. Lang D.J. CMV Immunization status, prospects, and problems . Rev Infect Dis. 2:1980;449-458.
13. Evans T.Y., Tyring S.K. Advances in antiviral therapy in dermatology. Dermatol Clin. 16:1998;409-420.
14. Misiani R., Bellavita P., Fenili D., et al. Interferon α-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med. 330:1994;751-756.
15. Pawlotsky J.-M., Dhumeaux D., Bagot M. Hepatitis C virus in dermatology. Arch Dermatol. 131:1995;1185-1193.
16. Domingo P., Ris J., Martinez E., Casas F. Erythema nodosum and hepatitis C [letter]. Lancet. 336:1990;1377.
17. Cacoub P., Lunel-Fabiani F., Le Thi Huong D. Polyarteritis nodosa and hepatitis C infection. Ann Intern Med. 116:1992;605-606.
18. Antinori S., Esposito R., Aliprandi C.A., et al. Erythema multiforme and hepatitis C [letter]. Lancet. 337:1991;428.
19. Levo Y., Borevic P.D., Kassab H.J., et al. Association between hepatitis B virus and essential mixed cryoglobulinemia. N Eng L Med. 296:1977;1501-1504.
20. Maggiore G., Grifeo S., Marzani M. Erythema nodosum and hepatitis B infection. J Am Acad Dermatol. 8:1983;539-548.
21. Divano M.C., Parodi A., Rebora A. Lichen planus, liver kidney microsomal (LKM1) antibodies and hepatitis C virus antibodies. Dermatology. 185:1992;132-133.
22. Dienstag J.L., Rhodes A.R., Bhan A.K., et al. Urticaria associated with acute viral hepatitis type B studies of pathogenesis . Ann Intern Med. 89:1978;34-40.
23. Pittsley R.A.A.A., Shearn M.A., Kaufman L. Acute hepatitis B simulating dermatomyositis. JAMA. 239:1978;959.
24. McElgunn P.S.J. Dermatologic manifestations of hepatitis B virus infection. J Am Acad Dermatol. 8:1983;539-548.
25. Colombo M., Gerber M.A., Vernace S.J., et al. Immune response to hepatitis B virus in children with papular acro-dermatitis. Gastroenterology. 73:1977;1103-1106.
26. Chervant-Breton J.R., Logeais B., Piboin M. Pyoderma gangrenosum pyoderma phagidenique . Ann Dermatol Venereol. 116:1989;577-589.
27. Tyring S.K. Human papillomavirus infections epidemiology, pathogenesis, and host immune response . J Am Acad Dermatol. 43:2000;S18-26.
28. de Miranda P., Blum M.R. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother. 12:(Suppl B):1983;29-37.
29. th edition. Philadelphia: McGraw-Hill Companies Inc, 2001:1313-47.
30. Spruance S.L., Stewart J.C.B., Rowe N.H., et al. Treatment of recurrent herpes simplex labialis with oral acyclovir. J Infect Dis. 161:1990;185-190.
31. Goldberg L.H., Kaufman R., Kirtz T.O., et al. The acyclovir study group. Long-term suppression of recurrent genital herpes with acyclovir a 5 year bench mark . Arch Dermatol. 239:1993;582-587.
32. Perrin L., Hirschel B. Combination therapy in primary HIV infection. Antiviral Res. 29:1996;87-89.
33. Spruance S.L., Hamill M.L., Hoge W.S., et al. Acyclovir prevents reactivation of herpes simplex labialis in skiers. JAMA. 260:1988;1597-1599.
34. Gilbert S., McBurney E. Use of valacyclovir for herpes simplex virus-1 (HSV-1) prophylaxis after facial resurfacing a randomized clinical trial of dosing regimens . Dermatol Surg. 26:2000;50-54.
35. Fife K.H., Barbarash R.A., Rudolph T., et al. Valacyclovir versus acyclovir in the treatment of first episode genital herpes infection results of an international, multi-center, double-blind, randomized clinical trial . Sex Trans Dis. 24:1997;481-486.
36. Tyring S.K., Douglas J.M., Corey L., et al. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. Arch Dermatol. 143:1998;185-191.
37. Reitano M., Tyring S.K., Lang W., et al. Valacyclovir for the suppression of recurrent genital herpes simplex infection a large-scale dose range finding study . J Infect Dis. 178:1998;603-610.
38. Cirelli R., Herne K., McCrary M., et al. Famciclovir review of clinical efficacy and safety . Antiviral Res. 29:1996;141.
39. Furman P.A., St Clair M.H., Spector T. Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase. J Biol Chem. 259:1984;9575.
40. Earnshaw D.L., Bacon T.H., Darlison S.J., et al. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother. 36:1992;2747.
41. Spruance S.L., Rowe N.H., Raborn G.W., et al. Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis a double-blind, dose-ranging, placebo-controlled, multicenter trial . J Infect Dis. 179:1999;303-310.
42. Spruance S.L., McKeough M.B. Combination treatment with famciclovir and a topical corticosteroid gel versus famciclovir alone for experimental ultraviolet radiation-induced herpes simplex labialis a pilot study . J Infect Dis. 181:2000;1906-1910.
43. Wall S.H., Ramey S.J., Wall F. Famciclovir as antiviral prophylaxis in laser resurfacing procedures. Plast Reconstr Surg. 104:1999;1103-1108.
44. Herne K., Cirelli R., Lee P., et al. Advances in antiviral therapy. Curr Opin in Dermatol. 3:1996;195-201.
45. Spruance S.L., Rea T.L., Thoming C., et al. Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group. JAMA. 277:1997;1374-1379.
46. Lazarus H.M., Belanger R., Candoni A., et al. Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients results of a multi-center, acyclovir-comtrolled trial. The Penciclovir Immunocompromised Study Group . Antimicrob Agents Chemother. 43:1999;1192-1197.
47. Arvin A.M., Prober C.G. Herpes simplex virus type 2 a persistent problem . N Engl J Med. 337:1997;1158-1159.
48. Lalezari J.P., Drew W.L., Glutzer E., et al. Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphorylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. J Infect Dis. 170:1994;570-572.
49. Meadows K.P., Tyring S.K., Pavia A.T., et al. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch Dermatol. 133:1997;987-990.
50. Lalezari J., Schackner T., Feinberg J., et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis. 176:1997;892-898.
51. Meadows K.P., Tyring S.K., Pavia A.T., et al. . Resolution of recalcitrant molluscum contagiousum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch Dermatol. 133:1997;987-990.
52. VanCutsem E., Snoeck R., Van Ranst M., et al. Successful treatment of squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphorylmethoxypropyl)cytosine. J Med Virol. 45:1995;230-235.
53. Zabawaski E.J., Sands B., Goetz D., et al. Treatment of verrucae vulgaris with topical cidofovir. JAMA. 278:1997;1236.
54. Nichols W.G., Boeck M. Recent advances in the therapy and prevention of CMV infections. J Clin Virol. 16:2000;25-40.
55. Colin J., Hoh H.B., Easty D.L., et al. Ganciclovir ophthalmic gel (Cirgan 0.015%) I the treatment of herpes simplex keratitis. Cornea. 16:1997;393-399.
56. Pillay D. Working party report management of herpes virus infections following transplantation . J Antimicrobial Chemother. 45:2000;729-748.
57. Gane E., Saliba F., Valdecasa G.J., et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of CMV disease in liver-transplant recipients. The oral ganciclovir International Transplantation Study Group. Lancet. 350:1997;1729-1733.
58. Hadziyannis S.T., Manesis E.K., Papkonstantinon A. Oral ganciclovir treatment in chronic hepatitis B infection a pilot study . J Hepatol. 31:1999;210-214.
59. Andersen K.P., Fox M.C., Brown-Driver V., et al. Inhibition of human CMV immediate-early gene expression by an antisense oligonucleotide complimetary to immediate-early RNA. Antimicrob Agents Chemother. 40:1996;2004-2011.
60. Leeds J.M., Henry S.P., Bistner S., et al. Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys. Drug Metab Dispos. 26:1998;670-675.
61. Habbema L. n-Docosanol 10% cream in the treatment of recurrent herpes labialis a randomized double-blind, placebo-controlled study . Acta Derm Venereol (Stockh). 76:1996;479-481.
62. Poehling K.A., Edwards K.M. Prevention, diagnosis, and treatment of influenza current and future options . Curr Opin in Peds. 13:2001;60-64.
63. McClellan K., Perry C.M. Oseltamivir a review of its use in influenza . Drugs. 61:2001;263-283.
64. Rooney J.F., Strauss S.E., Mannix M.L., et al. Oral acyclovir to suppress frequently recurrent herpes labialis a double-blind, placebo-controlled trial . Ann Intern Med. 39:1993;2759-2764.
65. + lymphocytes as prognostic markers of HIV-1 infection. Ann Int Med. 126:1997;946-954.
66. Thiers B.T. Antiretroviral therapy. J Am Acad Dermatol. 21:1989;443-454.
67. Douglas J.M., Critchlow C., Benedetti J., et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med. 310:1984;1551-1556.
68. Straus S.E., Takiff H.E., Seidlin M., et al. Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir. N Engl J Med. 310:1984;1545-1550.
69. Stanberry L.R., Cunningham A.L., Mindel A., et al. Prospects for control of herpes simplexvirus disease through immunization. Clin Infect Dis. 30:2000;549-566.
70. Straus S.E., Corey L., Burke R.L., et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet. 343:1994;1460-1463.
71. Straus S.E., Wald A., Kost R.G., et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B results of a placebo-controlled vaccine trial . J Infect Dis. 176:1997;1129-1134.
72. Stanberry L.R. Control of STDs-the role of prophylaxis vaccines against herpes simplex virus. Sex Trans Infect. 74:1998;391-394.
73. Stanberry L.R. Herpes. Vaccines for HSV. Dermatol Clin. 16:1998;811-816. , xiv.
74. Baron S., Tyring S.K., Fleischmann W.R., et al. The interferons mechanisms of action and clinical applications . JAMA. 266:(10):1991;1375-1383.
75. Birch C.J., Tysen D.P., Tachedjian G., et al. Clinical effects and in vitro studies of trifluorothymidines combined with interferon alpha for the treatment of drug-resistant and -sensitive herpes simplex viral infections. J Infect Dis. 166:1992;108-112.
76. Spruance S.L., Tyring S.K., Smith M.H., Meng T.-C. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes a pilot study . J Infect Dis. 184:2001;196-200.
77. Lai C.L., Chien R.n, Leung N., et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 339:1998;61-68.
78. Dienstag J.L., Schiff E.R., Wringht T.L., et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 341:1999;1256-1263.
79. Havia M., Benfield P. Interferon alpha 2a a review of its pharmacological properties and therapeutic use in the management of viral hepatitis . Drugs. 50:1995;873-896.
80. Sokal E.M., Roberts E.A., Mieli-Vergani G., et al. A dose-ranging study of the pharmacokinetic, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B. Antimicrob Agents Chemotherap. 44:2000;590-597.
81. Lau D.T., Everhart J., Kleiner D.E., et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alpha. Gastroenterology. 113:1997;1660-1667.
82. Yoshida H., Shiratori Y., Moriyama M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis in Japan 1141T Study Group. Inhibition of hepatocellular carcinogenesis by interferon therapy . Ann Intern Med. 131:1999;174-181.
83. Zeuzem S., Feinman V., Rasenack J., et al. Peg interferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 343:2000;1666-1672.
84. Baker G.E., Tyring S.K. Therapeutic appraoches to papilloma virus infections. Dermatol Clin. 15:1997;331-340.
85. Gilbert B.E., Knight V. Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother. 30:1986;201-205.
86. Long C.E., Voter K.Z., Barker W.H., et al. Long-term follow-up of children hospitalized with respiratory syncytial virus lower respiratory tract infection and randomly treated with ribavirin or placebo. Pediatr Infect Dis J. 16:1997;1023-1028.
87. Randolph A.G., Wang E.E. Ribavirin for resepiratory syncytial virus lower respiratory tract infection. A systemic overview. Arch Pediatr Adolesc Med. 150:1996;942-947.
88. Englund J.A., Piedra P., Ahn Y.M., et al. High-dose, short duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J Pedatr. 125:1994;635-641.
89. Rodriguez W.J., Hall C.B., Welliver R., et al. Efficacy and safety of aerosolized ribavirin in young children hospitalized for influenza a double-blind, multicenter, placebo-controlled trial . J Pediatr. 125:1994;129-135.
90. Tyring S.K., Edwards L., Cherry L.K., et al. Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. Arch Dermatol. 143:1998;33-38.
91. Baker G.E., Tyring S.K. Therapeutic approaches to papillomavirus infections. Dermatol Clin. 15:1997;331-340.
92. White C.J. Clinical trials of varicella vaccine in healthy children. Infect Dis Clin North Am. 10:1996;595.
93. Watson B., Rothstein E., Berstein E., et al. Safety and cellular humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J Infect Dis. 172:1995;217-219.
94. LaRussa P., Steinberg S., Gershon A.A. Varicella vaccine for immunocompromised children results of collaborative studies in the United State and Canada . J Infect Dis. 174:1996;S320.
95. White C.J. Clinical trials of varicella vaccine in healthy children. Infect Dis Clin N Am. 10:1996;595-608.
96. Rodriguez W.J. Management strategies for respiratory syncytial virus infections in infants. J Pediatr. 135:1999;S45-50.
97. Ghosh S, Champlin RE, Englund et al. Respiratory syncytial virus upper respiratory tract illness in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Trans 2000;25:751-5.
98. Englund J.A. Prevention strategies for respiratory syncytial virus passive and active immunization . J Pediatr. 135:1999;S38-41.
99. Koff R.S. Hepatitis A, hepatitis B, and combination hepatitis vaccines for immunoprophylaxis an update . Dig Dis Sci. 47:2002;1183-1194.
100. Winstrom J., Ahlm C., Lundberg S., et al. Booster vaccination with recombinant hepatitis B vaccine four years after primary with a single dose. Vaccine. 17:1999;2162-2165.
101. Cox N.J., Subbaro K. Influenza. Lancet. 354:1999;1277-1282.
102. Spamboulian D., Bonvehi P.E., Nacinovich F.M., et al. Influenza. Infect Dis Clin N Am. 14:2000;141-166.
103. Malhotra A., Krilov L.R. Influenza and respiratory syncytial virus update on infection, management, and prevention . Pediatr Clin N Am. 47:2000;353-372.
104. Cassidy W.M., Watson B., Ioli N.A., et al. A randomized trial of alternative two and three dose hepatitis B vaccincation regimens in adolescents antibody responses, safety, and immunologic memory . Pediatrics. 107:2001;626-631.